Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 767 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Extension of Indications for Darolutamide January 31, 2023 A Genome-Wide Association Study of irAEs Identifies New Genome-Wide Significant Associations... January 20, 2023 ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March March 14, 2025 Dr Ian Walker on Smoking: ‘The killer behind the counter’ March 17, 2023 Load more HOT NEWS Let’s talk about HPV: 6 common questions answered Immunotherapy, Liquid Biopsy, and Treatment Combinations: Research from the 2024 ASCO... Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom The Appraisal – Does a charity have a role in biotech...
